Levitee Labs Inc. to report that it has entered into a financing agreement for up to $12 million for further business expansion. The secured loan facility (the ?Loan?) was arranged by RiverFort Global Capital Ltd. (a UK firm) and the Loan is from RiverFort Global Opportunities PCC Ltd. (?RiverFort? or the "Lender"). The Company will utilize the proceeds from the Loan to support the Company?s prospective future acquisitions of several assets in the clinics, pharmacies and mental health space as well as for working capital purposes. Pursuant to the terms of the Loan, Levitee has agreed to draw down an initial $2.5 million tranche (?Tranche 1?), with this debt maturing on October 20th, 2023 (the ?Maturity Date?), with interest payable by Levitee in an amount equal to 10% per annum of the amount of the Tranche 1 advance. Any subsequent advances under the Loan, which will be entirely at the discretion of Levitee, will be subject to interest payable by Levitee in an amount equal to 20%, to be applied to the term between the date of the relevant advance date and the Maturity Date. The closing of Tranche 1, and each subsequent tranche of the Loan, will be subject to the satisfaction of customary closing conditions involving Levitee and RiverFort, including the final regulatory approval by the Canadian Securities Exchange.